The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2021 | Management of relapsed T-cell lymphoma
Steven Horwitz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses strategies to treat relapsed T-cell lymphoma. Patients with relapsed T-cell lymphoma who enter complete remission are more likely survive up to five years after treatment and certain subtypes including patients with angioimmunoblastic T-cell lymphoma will have especially good response rates. Dr Horwitz additionally mentions the need for novel therapies to serve as a bridge to allogeneic stem cell transplantation for complete remission. For transplant-ineligible patients, treatments such as valemetostat, romidepsin, or duvelisib can provide long-term efficacy for patient with few side effects. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
